… the inability of cells to detect DNA damage or to induce apoptosis. Towards an understanding
of the molecular basis of the cellular response to cisplatin-based chemotherapy in NSCLC, …

… with poor response and survival in cisplatin-treated patients. The lack of DNA adducts in
cell … is still the scaffolding of combination chemotherapy in non-small cell lung cancer (NSCLC). …

… PET for the assessment of chemotherapy response in patients with non–small cell lung cancer.
… Fractional changes in tumor glucose use were stratified by the median value and also the …

… The success of chemotherapeutic measures in the treatment of small cell lung cancer has
… rates ranging from 17 to 3 1 o/o and four trials have shown response rates of less than 10%. …

… proved to be ground-breaking as it yielded responses comparable to anthracycline-based …
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: …

… the early metabolic response to chemotherapy in patients with non–small cell lung cancer
and to … Methods: We studied 16 patients with non–small cell lung cancer as they followed 2 …

… antiapoptotic factors, or altered cell cycling or transcription factors. … cell lung cancer (SCLC)
resistance to chemotherapy include MRP (for platinum-based combination chemotherapy) …

… % in patients with no metabolic response. These findings indicate that PET … chemotherapy
at an early stage of treatment. To our knowledge, monitoring of tumor response in lung cancer …

… independent predictor for chemotherapeutic response in our … apparent in chemotherapeutic
regimens and response rates. … immune cells and malignant cells in tumor microenvironment…

… lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with
… A surrogate for survival, such as pathological response to neoadjuvant chemotherapy, has …